Clinical Trials Browser

sacituzumab govitecan × Gastrointestinal × Clear all

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Phase 1 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06329869 2024-12-02

SG-ESCC

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06243393 2024-07-10

TROPHIT1

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 2 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms